44 MILTON AVENUE, ALPHARETTA, GA
Reports Fourth Quarter and Full Year 2025 Financial Results
Special Meeting Held; Matters Approved by Shareholders on March 11, 2026
CEO Letter to Shareholders: The Year in Review, The Year Ahead
Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
Dogwood Therapeutics Enters Equity Distribution Agreement for $8.56M
Stockholders Approve Second Amended Equity Incentive Plan - Dogwood Therapeutics
Reports Third Quarter 2025 Financial Results
Investor Presentation
FY 2025
Q3
Q2
Q1
FY 2024
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Amended Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Free Writing Prospectus